FeesSafety
Pluang+

LeonaBio advances Phase 3 trial for breast cancer drug lasofoxifene, expects data in 2H 2027

Company Fundamentals
16 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
LeonaBio advances Phase 3 trial for breast cancer drug lasofoxifene, expects data in 2H 2027

LeonaBio reported Q3 2026 financial results and progress on its Phase 3 ELAINE-3 trial for lasofoxifene, targeting ER+, HER2-, ESR1-mutated metastatic breast cancer. Enrollment is expected to complete in Q4 2026, with topline data anticipated in the second half of 2027. The company highlighted lasofoxifene's potential to improve treatment outcomes for patients resistant to current therapies. Financially, LeonaBio's cash position was $32.3 million at quarter-end, with increased R&D expenses driven by clinical trial activities.

LeonaBio's Q3 2026 financial results and business update provide context for readers. For those following the health sector, 31 of 150 priced US stocks rose while 118 fell on Pluang. Notable movers include NUWE at USD 4.53 with a -7.55% change, ACB at USD 4.60 with a -6.88% change and 100% sell order activity, and HRTX at USD 0.29 with a -6.57% change and balanced buy/sell orders. This data is as of Nov 17, 2026 03:31 WIB.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App